



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61P 17/08* (2006.01)
A61K 31/437 (2006.01) *A61P 17/10* (2006.01)
A61P 17/00 (2006.01) *A61P 17/14* (2006.01)
A61P 17/02 (2006.01) *A61P 17/16* (2006.01)
A61P 17/04 (2006.01) *A61P 35/00* (2006.01)
A61P 17/06 (2006.01)

(21) International Application Number:

PCT/EP2012/076191

(22) International Filing Date:

19 December 2012 (19.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/578,677 21 December 2011 (21.12.2011) US
61/666,430 29 June 2012 (29.06.2012) US

(71) Applicant: **LEO PHARMA A/S** [DK/DK]; Industriparken
55, DK-2750 Ballerup (DK).

(72) Inventors: **NIELSEN, Simon Feldbæk**; c/o LEO Pharma
A/S, Industriparken 55, DK-2750 Ballerup (DK).
LARSEN, Jens Christian Højland; c/o LEO Pharma A/S,
Industriparken 55, DK-2750 Ballerup (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS

(57) Abstract: The present invention relates to novel [1,2,4]triazolopyridine compounds with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.



WO 2013/092739 A1